Forte Biosciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
3060 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Mailing Address
3060 PEGASUS PARK DRIVE, DALLAS, TX, 75247
Phone
(310) 618-6994
Fiscal Year End
1231
EIN
261243872
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 29, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 9, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Positive Phase 1b study results for FB102 in celiac disease showing improved gut health.
- Initiation of Phase 2 study for celiac disease with results expected in H1 2026.
Insider Trading
BUY
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.